VPM087A
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$325,744
Transactions
5
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $325,744 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $325,744 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE IB STUDY OF GEVOKIZUMAB IN COMBINATION WITH STANDARD OF CARE ANTI-CANCER THERAPIES IN PATIENTS WITH METASTATIC COLORECTAL CANCER, GASTROESOPHAGEAL CANCER AND RENAL CELL CARCINOMA | Novartis Pharmaceuticals Corporation | $325,744 | 0 |
Top Doctors Receiving Payments for VPM087A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $325,744 | 5 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $325,744
Product Information
- Type Biological
- Total Payments $325,744
- Total Doctors 0
- Transactions 5
About VPM087A
VPM087A is a biological associated with $325,744 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $325,744 was paid across 5 transactions to 0 doctors.
The most common payment nature for VPM087A is "Unspecified" ($325,744, 100.0% of total).
VPM087A is associated with 1 research study, including "PHASE IB STUDY OF GEVOKIZUMAB IN COMBINATION WITH STANDARD OF CARE ANTI-CANCER THERAPIES IN PATIENTS WITH METASTATIC COLORECTAL CANCER, GASTROESOPHAGEAL CANCER AND RENAL CELL CARCINOMA" ($325,744).